4.7 Article

Microvascular complications of impaired glucose tolerance

期刊

DIABETES
卷 52, 期 12, 页码 2867-2873

出版社

AMER DIABETES ASSOC
DOI: 10.2337/diabetes.52.12.2867

关键词

-

资金

  1. NCRR NIH HHS [M01-RR00042NS38849, MO1 RR00064] Funding Source: Medline
  2. NINDS NIH HHS [NS42065, NS36778, NS40458, R21-NS-41634] Funding Source: Medline
  3. NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000064, M01RR000042] Funding Source: NIH RePORTER
  4. NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS041634, R01NS036778, R01NS040458] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Impaired glucose tolerance (IGT) serves as a marker for the state of insulin resistance and predicts both large-and small-vessel vascular complications, independent of a patient's progression to diabetes. Patients with IGT are at significantly increased risk for death and morbidity due to myocardial infarction, stroke, and large-vessel occlusive disease. IGT is more predictive of cardiovascular morbidity than impaired fasting glucose, probably because it is a better surrogate for the state of insulin resistance. IGT is also independently associated with traditional microvascular complications of diabetes, including retinopathy, renal disease, and polyneuropathy, which are the topics of this review. Inhibition of nitric oxide-mediated vasodilation, endothelial injury due to increased release of free fatty acids and adipocytokines from adipocytes, and direct metabolic injury of endothelial and end-organ cells contribute to vascular complications. Early detection of IGT allows intensive diet and exercise modification, which has proven significantly more effective than drug therapy in normalizing postprandial glucose and inhibiting progression to diabetes. To what degree intervention will limit recognized complications is not known.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据